Pediatric renal transplant recipient survival continues to improve, but ABMR remains a significant contributor to graft loss. ABMR prognostic factors to guide treatment are lacking. C4d staining on biopsies, diagnostic of ABMR, is associated with graft failure.
| INTRODUCTION
Pediatric renal transplantation has dramatically improved patient survival and quality of life for children with end-stage renal disease. The discovery of recipient alloantibodies to donor antigens led to improved renal transplant outcomes. 1, 2 Despite the increased sensitivity and specificity of DSA testing, ABMR remains a significant cause of acute and chronic renal allograft injury. 3 ABMR is the major contributor to late allograft failure. 4 In ABMR, antibodies bind to allograft endothelial antigens expressed on the peritubular and glomerular capillaries, leading to necrosis, apoptosis, and ischemic injury. 5 In addition to the presence of circulating DSA, the diagnosis of acute ABMR requires histological evidence of recent endothelial injury, such as glomerulitis or peritubular capillaritis and linear peritubular capillary C4d staining. 6, 7 A byproduct of complement fixation and activation, C4d remains bound to the vascular endothelium in ABMR. 8 Histological staining of C4d therefore is a useful biomarker of ABMR and is strongly associated with graft failure. [9] [10] [11] [12] [13] Peritubular capillary C4d staining detected by immunohistochemistry is less sensitive than immunofluorescence, which is taken into account by the Banff classification in determining the threshold for positivity. Glomerular C4d staining is non-specific on immunofluorescence . After a diagnosis of rejection is made, our protocol is to perform routine follow-up biopsies at 6-8 weeks after the initial biopsy to assess the response to treatment unless there is a contraindication such as active infection. The institutional review board approved the study.
| Data collection
We noted demographic and pretransplant clinical data, including sex, Serum creatinine and UPCR (mg protein/mg creatinine) were recorded at baseline, at the time of ABMR diagnosis, and 12 months after ABMR diagnosis. eGFR was calculated using the updated Schwartz equation. 18 Proteinuria was defined as UPCR > 0.2. 19, 20 We recorded any use of antiproteinuric medications (angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers) during the study period.
| Outcomes
The primary outcome 12 months after ABMR diagnosis was a composite of (i) ≥50% reduction in eGFR from baseline to 12 months after ABMR diagnosis, (ii) transplant glomerulopathy on biopsy, or (iii) graft failure. UPCR 12 months after ABMR diagnosis was the secondary outcome. Our primary predictor was persistent C4d positivity (C4d+) on follow-up biopsy.
| Statistical analyses
Categorical variables were summarized with frequency distributions and continuous variables were summarized by mean with standard deviation (SD) or median with IQR. Between-group differences were analyzed (ii) associated with a >10% change in the significant predictor-outcome estimate. Creatinine at baseline and at ABMR diagnosis was a priori included in the primary outcome model, and the UPCR at baseline and at ABMR diagnosis was a priori included in the secondary outcome model.
We used logistic regression modeling for the primary outcome and general linear regression modeling for the secondary outcome. Enterprise
Guide software, Version 7.11 of the SAS System for Windows (SAS Institute Inc., Cary, NC, USA) was used for all analyses.
| RESULTS

| Baseline and transplant characteristics
Subjects were racially diverse (47% Hispanic, 29% Caucasian, 12%
African American, and 12% Asian) and 71% were male (Table 1) .
N = 17
Yes No n = 7 (41%) n = 10 (59%) 
Antigen match ≤ 1/6 13 (76%) 4 (57%) 9 (90%) 
T A B L E 1 Patient characteristics by primary outcome
One subject (6%) had a prior renal transplant and 35% were sensitized prior to transplantation. Of the six subjects who were sensitized, three received pretransplant (2) or perioperative (1) intravenous immunoglobulin for desensitization but no further desensitization was performed. The majority (76%) received less than two of six antigenmatched allografts. All subjects received induction immunosuppression, predominantly with ATG (76%). The majority of subjects (65%)
were on steroid-free maintenance immunosuppression, and all subjects received tacrolimus and mycophenolate. Three subjects (18%)
had delayed graft function. Table 2 lists subjects' ABMR characteristics. The mean time to rejection was 21.0 months after transplant and 53% had documented noncompliance. The majority of subjects had class II immunodominant DSA (76%), most commonly DQ (71%), and 94% were C1q-positive.
| ABMR characteristics
Mixed rejection was common, with concurrent acute T cell-mediated
tubulointerstitial rejection (TCMR grade I, 65%) and/or vascular rejection (TCMR grade ≥II, 6%). The majority of biopsies were graded Banff IB (35%) but 29% were negative for TCMR. Glomerulitis was present in 24% of cases. One subject had evidence of acute and chronic active ABMR on index biopsy (subject 15, Banff cg = 1). Complete Banff scores for the histological and immunohistochemical components of each index biopsy are shown in Table S1 .
Overall, ABMR treatment was heterogeneous. All subjects received intravenous immunoglobulin, 76% received rituximab, 71%
received high-dose pulse steroids, and 53% received ATG (the latter 2 agents were used to treat concomitant TCMR). Eighteen percent received plasmapheresis and 12% received bortezomib. Of the eight subjects who were on steroid-free maintenance immunosuppression, 50% were changed to a steroid-based protocol after ABMR diagnosis.
| Persistent C4d staining
Forty-one percent of subjects were persistently C4d+ (C4d > 0) on their follow-up biopsy (Tables S2 and S3 Creatinine at diagnosis (mg/dL) 
| Primary outcome
Seven subjects (41%) reached the composite primary outcome at 12 months after ABMR diagnosis ( Figure 2 ). Three subjects had a 50% reduction in their eGFR, two subjects had transplant glomerulopathy, and three subjects had graft failure. One of the subjects whose graft failed also had transplant glomerulopathy. There were no differences in baseline, transplant, or ABMR characteristics between groups, including creatinine at baseline and at ABMR diagnosis, except that subjects who reached the primary outcome were older at transplant two groups did not differ in rates of persistent C4d+ (43% vs 40%, P = 1.00). Table 3 shows the final regression model for the primary outcome at 12 months, controlling for creatinine at baseline and at ABMR diagnosis. Persistent C4d+ was not significantly associated with the primary outcome (OR 1.81, 95% CI 0.18-17.87, P = .61).
| Secondary outcome
Data on proteinuria at 12 months after ABMR diagnosis were available in 11 subjects (65%). The median (IQR) UPCR at 12 months was 0.23 . UPCR at baseline (correlation coefficient .37, P = .14) and at ABMR diagnosis (correlation coefficient .5, P = .04) were correlated with UPCR at 12 months. Table 3 
| DISCUSSION
Our study identified a novel independent risk factor associated with adverse outcomes after acute/active ABMR in pediatric renal transplant recipients. Persistent C4d+ on follow-up biopsies was associated with a higher UPCR 12 months after ABMR diagnosis. Proteinuria is a known marker of chronic kidney disease in transplant recipients and predicts graft failure. [21] [22] [23] The reason for this persistent C4d staining is unclear and as C4d staining is not specific for ABMR, could indicate dynamic humoral activity, accommodation, continued microvascular damage, chronic ABMR, or repeated episodes of acute ABMR.
11,24-26
Tissue-bound C4d generally indicates recent immunologic activity, usually within weeks. 24 There was no difference in C4d persistence by time to follow-up biopsy (median 2.0 months). Our study provides evidence supporting the prognostic value in staining for C4d on follow-up biopsies when evaluating a patient's response to ABMR treatment.
The association between persistent C4d+ and UPCR at 12 months was independent of the UPCR at baseline and at ABMR diagnosis, both of which were also significantly associated with UPCR at 12 months. This is consistent with the literature, wherein worse proteinuria at the time of ABMR diagnosis is associated with decreased treatment response and worse ABMR outcomes. 27 We also controlled for concomitant TCMR, and consistent with previous studies in adult transplant recipients, we found that TCMR was associated with worse outcomes. 14, 28, 29 To our knowledge, this study is the largest to date to investigate ABMR in pediatric renal transplant recipients. Thirty-five percent of our subjects were sensitized at the time of transplant but this had no effect on outcomes. Steroid-free immunosuppression had no effect on outcomes and was a common maintenance immunosuppression protocol in our population. Non-compliance was common but we could not detect a difference in outcomes given the small sample size.
Our study did not find any differences according to immunodominant DSA but this is likely because the majority of our subjects had class II DSA and all but one subject was C1q-positive. Class II DSA, and in particular C1q-positive DSA, are associated with a higher risk of C4d
